PARP inhibitors: clinical development, emerging differences, and the current therapeutic issues

Following years in development, poly-adenosyl-ribose polymerase (PARP) inhibitors continue to advance the treatment of ovarian and breast cancers, particularly in patients with pathogenic BRCA mutations. Differences in clinical trial design have contributed to distinct indications for each of the PA...

Descripción completa

Detalles Bibliográficos
Autores principales: Murthy, Pooja, Muggia, Franco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: OAE Publishing Inc. 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8992523/
https://www.ncbi.nlm.nih.gov/pubmed/35582575
http://dx.doi.org/10.20517/cdr.2019.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8992523/
https://www.ncbi.nlm.nih.gov/pubmed/35582575
http://dx.doi.org/10.20517/cdr.2019.002

Ejemplares similares